Publicación:
Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model

Vista sencilla de ítem
dc.contributor.authorDíaz, Andrés
dc.contributor.authorSerrano Coll, Héctor
dc.contributor.authorBotero, Yesica
dc.contributor.authorCalderón Rangel, Alfonso
dc.contributor.authorArteta Cueto, Ariel
dc.contributor.authorGastelbondo Pastrana, Bertha Irina
dc.contributor.authorGuzmán Terán, Camilo Antonio
dc.contributor.authorRivero, Ricardo
dc.contributor.authorMartínez Bravo, Caty Milena
dc.contributor.authorMárquez, Tania
dc.contributor.authorArrieta Bernate, German Javier
dc.contributor.authorMattar Velilla, Ameth Salim
dc.contributor.corporatenameCorporación Universitaria del caribe - CECAR
dc.contributor.researchgroupSalud Pública y Auditoría en Salud
dc.date.accessioned2025-08-26T16:58:42Z
dc.date.issued2022
dc.description.abstractIntroduction: Although more than half of the world’s population is already vaccinated, the appearance of new variants of concern puts public health at risk due to the generation of new immunogens against the virus as a crucial and relevant strategy in the control of these new variants. Methods: A preclinical study used a potential vaccine candidate (RBD, SARS-CoV-2). Four groups of BALB/c mice were used, a control group, an adjuvant group, a group inoculated with one dose of RBD subunit protein, and the fourth group inoculated with two doses of RBD subunit protein. Results: No inflammatory or cellular changes were shown in the mice’s anatomopathological evaluation. Higher kinetics and 75% seroconversion were obtained in the mice inoculated with two doses of RBD (P < 0.0001). Conclusions: The application of two doses of the RBD vaccine candidate in BALB/c mice proved safe and immunogenic against SARS-CoV-2
dc.description.researchareaAuditoría en salud
dc.description.researchareaSalud Pública
dc.format.extent5 páginas
dc.format.mimetypeapplication/pdf
dc.identifier.eissn1477-8939
dc.identifier.urihttps://repositorio.cecar.edu.co/handle/cecar/10739
dc.language.isoeng
dc.publisher.placeColombia
dc.relation.citationendpage5
dc.relation.citationstartpage1
dc.relation.citationvolumeVolumen 49
dc.relation.ispartofjournalTravel Medicine and Infectious Disease
dc.relation.referencesWorld Health Organization. Coronavirus Disease (COVID-19) Dashboard [Internet]. 2022. Available from: https://covid19.who.int/.
dc.relation.referencesOur World in Data. Coronavirus (COVID-19) vaccinations [Internet], Available from: https://ourworldindata.org/covid-vaccinations; 2022.
dc.relation.referencesGarg R, Gautam P, Suroliya V, Agarwal R, Bhugra A, Kaur US, et al. Evidence of early community transmission of Omicron (B1.1.529) in Delhi- A city with very high seropositivity and past-exposure! Trav Med Infect Dis 2022;46:102276. Jan 1; 2022.01.10.22269041. ISSN 1477-8939, https://doi.org/10.1016/j.tmaid.2022.10 2276.
dc.relation.referencesWilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv 2021 Jan 1. 2021.12.07.21267432.
dc.relation.referencesLan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020 May;581 (7807):215–20.
dc.relation.referencesOrganizacion Mundial de Sanidad Animal. Utilizaci ´ on de animales en la ´ investigacion y educaci ´ on [Internet]. 2011. Available from: ´ https://www.oie.int/fi leadmin/Home/esp/Health_standards/tahc/2011/es_chapitre_1.7.8.htm.
dc.relation.referencesAVMA. AVMA. Guidelines for the Euthanasia of Animals: 2020 Edition [Internet]. 2020. Available from: https://www.avma.org/sites/default/files/2020-01/2020- Euthanasia-Final-1-17-20.pdf.
dc.relation.referencesWorld Health Organization. Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines [Internet]. 2013. Available from: https://www. who.int/biologicals/areas/vaccines/ADJUVANTS_Post_ECBS_edited_clean_Guide lines_NCE_Adjuvant_Final_17122013_WEB.pdf.
dc.relation.referencesEuropean Medicines Agency. Guideline on adjuvants in vaccines for human use [Internet]. 2005. Available from: https://www.ema.europa.eu/en/documents/scie ntific-guideline/guideline-adjuvants-vaccines-human-use-see-also-explanato ry-note_en.pdf.
dc.relation.references[United States Food and Drug Administration Center for Biologics evaluation and Research. Development and licensure of vaccines to prevent COVID-19 [Internet], Available from: https://www.fda.gov/regulatory-information/search-fda-guidan ce-documents/development-and-licensure-vaccines-prevent-covid-19; 2020.
dc.relation.referencesAcrobiosystems Mouse. Anti-SARS-CoV-2 Antibody IgG Titer Serologic Assay kit [Internet]. 2021. Available from: https://www.acrobiosystems.com/P3842-Mouse %C2%A0Anti-SARS-CoV-2%C2%A0Antibody%C2%A0IgG%C2%A0Titer%C2% A0Serologic%C2%A0Assay%C2%A0kit.html.
dc.relation.referencesKeirstead ND, Janovitz EB, Meehan JT, LeRoy BE, Megill JR, Peterson RA, et al. Scientific and regulatory policy committee points to consider*: review of scientific and regulatory policy committee points to consider: review of current practices for ultrastructural pathology evaluations in support of nonclinical toxicology studies. Toxicol Pathol 2019 Jun;47(4):461–8.
dc.relation.referencesAn Y, Li S, Jin X, Han JB, Xu K, Xu S, Han Y, Liu C, Zheng T, Liu M, Yang M, Song TZ, Huang B, Zhao L, Wang W, R A, Cheng Y, Wu C, Huang E, Yang S, Wong G, Bi Y, Ke C, Tan W, Yan J, Zheng YT, Dai L, Gao GF. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerg Microbes Infect 2022 Dec;11(1):1058–71. https://doi.org/ 10.1080/22221751.2022.2056524. PMID: 35311493; PMCID: PMC9009945.
dc.relation.referencesYang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 2021 Aug;21(8):1107–19.
dc.relation.referencesYang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020 Oct;586 (7830):572–7.
dc.relation.referencesDai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021 Feb;21(2):73–82.
dc.relation.referencesLamerton RE, Marcial-Juarez E, Faustini SE, Perez-Toledo M, Goodall M, Jossi SE, et al. In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens. medRxiv 2021 Jan 1. 2021.11.22.21266681.
dc.relation.referencesAbbas A, Lichtman A, Pillai S. Cellular and molecular immunology [Internet]. Elsevier/Saunders; 2015. Available from: https://www.ncbi.nlm.nih.gov/nlm catalog/101630458.
dc.relation.referencesCoronavirus OECD. COVID-19)vaccines for developing countries: an equal shot at recovery. Available from: https://read.oecd-ilibrary.org/view/?ref=1060_1060 300-enj5o5xnwj&title=Coronavirus-COVID-19-vaccines-for-developing-countriesAn-equal-shot-at-recovery.
dc.relation.referencesRodríguez-Morales A, Mattar S, Gonz ´ alez TM. Vacunas para COVID-19 - ´ ¿Podemos evitar volver a vivir en un pueblo fantasma? Rev MVZ Cordoba 2021;26(2):e2350. ´ https://doi.org/10.21897/rmvz.2350.
dc.rightsDerechos reservados - Corporación Universitaria de Caribe - CECAR
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2
dc.rights.licenseAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourcehttps://doi.org/10.1016/j.tmaid.2022.102427
dc.subject.proposalPublic health
dc.subject.proposalSurveillance
dc.subject.proposalVaccination
dc.subject.proposalSpike glycoprotein
dc.subject.proposalCoronavirus
dc.titleImmunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine modeleng
dc.typeArtículo de revista
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/article
dc.type.redcolhttp://purl.org/redcol/resource_type/ART
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model.pdf
Tamaño:
3.92 MB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
14.49 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

BAF. Salud Pública y Auditoria en Salud (SPAS)